← Eichor
Condition: Advanced Lymphoma Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Advanced Lymphoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Celecoxib Plus R-CHOP vs R-CHOP in Newly Diagnosed Advanced CD5+ DLBCL
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT07494565BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
Phase 1/Phase 2 · 25 location(s) · BioInvent International AB · NCT04752826Sequential Infusion of CD146-Targeted and HER2-Targeted CAR T Cells in Patients With Advanced Sarcomas
Phase 1/Phase 2 · 1 location(s) · Essen Biotech · NCT07066982A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer
Phase 1/Phase 2 · 6 location(s) · Recursion Pharmaceuticals Inc. · NCT06678659Fixed-Duration Zanubrutinib, Bendamustine, and Obinutuzumab (ZBG) in Treatment-Naïve Advanced Stage Follicular Lymphoma
NA · 1 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT07126678Odronextamab in Low Tumor Volume Advanced FL
Phase 2 · 1 location(s) · Gottfried von Keudell, MD PhD · NCT07128641This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Tor
Phase 1 · 3 location(s) · Zumutor Biologics Inc. · NCT06451497Trial for Patients w/ Advanced Hematologic Malignancies Undergoing Allogeneic HCT
Phase 1 · 1 location(s) · Stanford University · NCT06551584The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
Phase 1/Phase 2 · 11 location(s) · AVM Biotechnology Inc · NCT04329728A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.
Phase 1 · 17 location(s) · Arvinas Inc. · NCT06393738At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Phase 2 · 2 location(s) · Mayo Clinic · NCT05969860A Phase I/II Clinical Study of CTS3497 in Patients With MTAP Deficient Malignacies
Phase 1/Phase 2 · 1 location(s) · CytosinLab Therapeutics Co., Ltd. · NCT06971523A Safety, Pharmacokinetic and Clinical Activity Study of NUC-7738 in Patients With Advanced Solid Tumours and Lymphoma
Phase 1/Phase 2 · 9 location(s) · NuCana plc · NCT03829254A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas
Phase 1 · 38 location(s) · CStone Pharmaceuticals · NCT05279300IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas
Phase 1 · 13 location(s) · Iksuda Therapeutics Ltd. · NCT05365659Multilayer Biological Characterization of Advanced Follicular Lymphoma: a Translational Study From FIL_FOLL12 Trial
Phase N/A · 26 location(s) · Fondazione Italiana Linfomi - ETS · NCT05816850A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Ac
Phase 1/Phase 2 · 74 location(s) · Nuvalent Inc. · NCT05384626Trial for Local Ablative Treatment (LAT) Optimization in Patients With Advanced Non-Small Cells Lung Cancer (NSCLC) Pres
Phase 2 · 27 location(s) · Groupe Francais De Pneumo-Cancerologie · NCT06620835Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas
Phase 2 · 1 location(s) · University of Michigan Rogel Cancer Center · NCT05956041SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Phase N/A · 68 location(s) · Massive Bio, Inc. · NCT03452774Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study
Phase 2 · 1 location(s) · Zhejiang Provincial People's Hospital · NCT06534762Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
Phase 1/Phase 2 · 39 location(s) · CellCentric Ltd. · NCT04068597Pharmacokinetics and Safety Study of Pelabresib in Patients With Advanced Malignancies and Hepatic Impairment
Phase 1 · 8 location(s) · Novartis Pharmaceuticals · NCT07422610ID Of Prognostic Factors In Mycosis Fungoides/Sezary Syndrome
Phase N/A · 13 location(s) · Stanford University · NCT02848274Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
Phase 1 · 2 location(s) · Baylor College of Medicine · NCT01853631A Study to Investigate the Safety and Tolerability of SCR-6920 Capsule in Patients With Advanced Malignant Tumors
Phase 1 · 1 location(s) · Jiangsu Simcere Pharmaceutical Co., Ltd. · NCT05528055A Study of NX-1607 in Adults With Advanced Malignancies
Phase 1 · 17 location(s) · Nurix Therapeutics, Inc. · NCT05107674Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma
EARLY_Phase 1 · 6 location(s) · New York Medical College · NCT03719105Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
Phase 3 · 65 location(s) · Novartis Pharmaceuticals · NCT06784752Whole Body MRI in Oncology
Phase N/A · 3 location(s) · Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRS · NCT06895291
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.